Breaking News Instant updates and real-time market news.

BAX

Baxter

$82.01

-0.45 (-0.55%)

, SNY

Sanofi

$46.65

0.25 (0.54%)

09:09
12/02/19
12/02
09:09
12/02/19
09:09

Baxter acquires Seprafilm Adhesion Barrier from Sanofi for $350M

Baxter International (BAX) entered into a definitive agreement to acquire Seprafilm Adhesion Barrier and related assets from Sanofi (SNY). "The agreement is the latest example of Baxter's continued focus on acquiring products and technologies that have a strong strategic fit with the company's leading portfolio across the hospital, including in the operating room," the company said in a statement. The transaction contemplates a cash purchase price at closing of $350M and is expected to close no later than Q1 of 2020, following satisfaction of closing conditions. Seprafilm currently has sales in the U.S., Japan, China, South Korea and France, among others, according to Baxter. Sales of the proposed acquired products are expected to be approximately $100M in the 12 months following close, it added.

BAX

Baxter

$82.01

-0.45 (-0.55%)

SNY

Sanofi

$46.65

0.25 (0.54%)

  • 03

    Dec

  • 07

    Dec

  • 09

    Dec

BAX Baxter
$82.01

-0.45 (-0.55%)

07/26/19
RAJA
07/26/19
NO CHANGE
Target $95
RAJA
Outperform
Baxter price target raised to $95 from $84 at Raymond James
Raymond James analyst Lawrence Keusch raised his price target on Baxter shares to $95 from $84 following a "solid" quarter marked by outperformance in its Advanced Surgery, Pharmaceuticals, and Medication Delivery segments. In particular, the recent momentum in Medication Delivery gives him increasing confidence in Baxter's ability to accelerate growth in the second half, said Keusch, who keeps an Outperform rating on the stock.
09/10/19
PIPR
09/10/19
NO CHANGE
PIPR
Overweight
Baxter makes 'solid tuck-in' deal buying Cheetah Medical, says Piper Jaffray
After Baxter announced a deal to buy hemodynamic monitoring solutions maker Cheetah Medical for up to $230M in total consideration, Piper Jaffray analyst Matt O'Brien called the acquisition a "solid tuck-in" that presents significant cross-selling opportunities. Baxter continues to execute at a high level, according to O'Brien, who reiterated his Overweight rating on the stock.
10/08/19
JPMS
10/08/19
NO CHANGE
Target $94
JPMS
Overweight
Baxter reiterated as top large-cap pick at JPMorgan
After spending time with management, JPMorgan analyst Robbie Marcus has a "high level of confidence" in Baxter International's ability to reach its 2020 long-range plan targets that call for accelerating sales growth and 200 basis points of operating margin expansion in 2020. The U.S. government's initiative to move dialysis patients into the home could double Baxter's ~$500M Peritoneal Dialysis business over the next few years, Marcus tells investors in a research note. The analyst also sees potential upside from the company's "unlevered" balance sheet. He reiterates Baxter as his top large-cap pick with an Overweight rating and $94 price target.
10/24/19
PIPR
10/24/19
NO CHANGE
PIPR
Piper Jaffray says Baxter Q3 earnings 'OK,' but accounting overhang looms
Piper Jaffray analyst Matt O'Brien maintained an Overweight rating and $95 price target on Baxter after the company reported "OK" Q3 results that missed on revenue slightly, and announced "an investigation into certain fx-related accounting transactions that may result in material adjustments to the current and prior years' EPS." While the analyst believes the announcement will remain an overhang on the stock until it more is known or it is resolved, he is confident in the company's long-term outlook " given the improving secular and business trends in renal, U.S. med delivery, and pharma."
SNY Sanofi
$46.65

0.25 (0.54%)

09/23/19
GUGG
09/23/19
UPGRADE
GUGG
Buy
Sanofi upgraded to Buy on Dupixent's accelerating uptake at Guggenheim
Guggenheim analyst Seamus Fernandez upgraded Sanofi (SNY) to Buy from Neutral based on his view that Dupixent's accelerating uptake across Asthma and Atopic Dermatitis, and several other indications, should drive earlier than expected profitability of the Regeneron (REGN) antibody collaboration. He also believes that emerging markets growth should help stabilize the large established products and overall diabetes franchises and thinks that vaccines business growth looks sustainable. Fernandez, who also thinks pipeline expectations seem low, set a EUR96 price target on Sanofi shares.
09/23/19
GUGG
09/23/19
UPGRADE
Target $403
GUGG
Buy
Guggenheim upgrades Regeneron to Buy, says sentiment too negative
As previously reported, Guggenheim upgraded Regeneron (REGN) to Buy from Neutral as analyst Yatin Suneja noted that Eylea has maintained its dominance in the branded anti-VEGF retinal disease market despite "stiff branded competition" from Roche's (RHHBY) Lucentis and off-label use of Roche's Avastin. Eylea's expansion into new indications has resulted in a diversified business and defensible market position, argued Suneja, who also believes the Street is substantially under-appreciating the market opportunity for Dupixent, which is expected to drive significant leverage in the Sanofi (SNY) antibody collaboration that recently became profitable. Suneja raised the price target on Regeneron shares to $403 from $355.
10/02/19
STFL
10/02/19
NO CHANGE
Target $45
STFL
Buy
Stifel remains buyer of Principia Biopharma into Q4 data readouts
Stifel analyst Derek Archila remains bullish and a buyer of Principia Biopharma (PRNB) shares ahead of the company's two Phase 2 readouts for PRN1008 in immune thrombocytopenia and pemphigus vulgaris. The shares could reach the mid-$50 range if results are positive, Archila tells investors in a research note. He believes the bogey for each study is not that high and keeps a Buy rating on Principia with a $45 price target. The two clinical catalysts, coupled with Phase 2 data expected in the first half of 2020 from the company's partnered program with Sanofi (SNY) in multiple sclerosis, offers "multiple shots for valuation creation" over the next nine months.
10/15/19
BOFA
10/15/19
NO CHANGE
BOFA
Europe 1 List changes at BofA/Merrill
BofA/Merrill added Roche (RHHBY) and Sanofi (SNY) to the Europe 1 List and removed AstraZeneca.

TODAY'S FREE FLY STORIES

SPT

Sprout Social

20:34
12/12/19
12/12
20:34
12/12/19
20:34
Syndicate
Sprout Social 8.824M share IPO priced at $17.00 »

The deal priced at the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 13

    Dec

SCHW

Charles Schwab

$51.08

1.48 (2.98%)

20:16
12/12/19
12/12
20:16
12/12/19
20:16
Upgrade
Charles Schwab rating change  »

Charles Schwab upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLUE

Bluebird Bio

$84.00

-2.97 (-3.41%)

20:08
12/12/19
12/12
20:08
12/12/19
20:08
Upgrade
Bluebird Bio rating change  »

Bluebird Bio upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AQST

Aquestive Therapeutics

$6.73

-0.97 (-12.60%)

20:07
12/12/19
12/12
20:07
12/12/19
20:07
Syndicate
Aquestive Therapeutics 7M share Secondary priced at $5.00 »

The deal priced below the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

BY

Byline Bancorp

$18.95

0.54 (2.93%)

19:56
12/12/19
12/12
19:56
12/12/19
19:56
Hot Stocks
Byline Bancorp initiates 3c per share cash dividend »

The dividend is payable…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

  • 18

    Dec

NXGN

NextGen Healthcare

$16.83

-1.28 (-7.07%)

19:08
12/12/19
12/12
19:08
12/12/19
19:08
Downgrade
NextGen Healthcare rating change at Cantor Fitzgerald »

NextGen Healthcare…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

AMOT

Allied Motion

$46.79

0.81 (1.76%)

18:57
12/12/19
12/12
18:57
12/12/19
18:57
Hot Stocks
Allied Motion CEO sells 10K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LILA

Liberty Latin America

$17.56

0.32 (1.86%)

, DISCA

Discovery

$32.36

0.28 (0.87%)

18:54
12/12/19
12/12
18:54
12/12/19
18:54
Hot Stocks
Liberty Latin America says Dr. John Malone retires from board »

Liberty Latin America…

LILA

Liberty Latin America

$17.56

0.32 (1.86%)

DISCA

Discovery

$32.36

0.28 (0.87%)

LGF.A

Lionsgate

$9.99

0.65 (6.96%)

LGF.B

Lionsgate

$9.35

0.7 (8.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HOCPY

Hoya Corp.

$0.00

(0.00%)

, TOSBF

Toshiba, also use TOSYY

$0.00

(0.00%)

18:43
12/12/19
12/12
18:43
12/12/19
18:43
Hot Stocks
Hoya to offer JPY12,900 per share in tender offer for Toshiba unit NuFlare »

Hoya Corporation (HOCPY)…

HOCPY

Hoya Corp.

$0.00

(0.00%)

TOSBF

Toshiba, also use TOSYY

$0.00

(0.00%)

TOSYY

Toshiba

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Dec

ADBE

Adobe

$305.76

2.01 (0.66%)

, SRPT

Sarepta

$100.39

-1.15 (-1.13%)

18:42
12/12/19
12/12
18:42
12/12/19
18:42
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: Adobe…

ADBE

Adobe

$305.76

2.01 (0.66%)

SRPT

Sarepta

$100.39

-1.15 (-1.13%)

DDOG

Datadog

$35.75

0.23 (0.65%)

RIG

Transocean

$5.94

0.28 (4.95%)

TPR

Tapestry

$26.35

0.515 (1.99%)

GTIM

Good Times Restaurants

$1.71

0.14 (8.92%)

ORCL

Oracle

$56.47

0.16 (0.28%)

AVGO

Broadcom

$327.39

7.53 (2.35%)

COST

Costco

$297.50

2.28 (0.77%)

CNC

Centene

$58.52

-0.13 (-0.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 12

    Dec

  • 12

    Dec

  • 12

    Dec

  • 12

    Dec

  • 13

    Dec

  • 23

    Jan

  • 23

    Mar

SRPT

Sarepta

$100.39

-1.15 (-1.13%)

18:40
12/12/19
12/12
18:40
12/12/19
18:40
Hot Stocks
Breaking Hot Stocks news story on Sarepta »

Sarepta up 28.5% after…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PHR

Phreesia

$28.67

0.1 (0.35%)

18:38
12/12/19
12/12
18:38
12/12/19
18:38
Syndicate
Phreesia 6.75M share Secondary priced at $26.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

SRPT

Sarepta

$100.39

-1.15 (-1.13%)

18:31
12/12/19
12/12
18:31
12/12/19
18:31
Hot Stocks
Breaking Hot Stocks news story on Sarepta »

Sarepta to resume trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADBE

Adobe

$305.76

2.01 (0.66%)

18:25
12/12/19
12/12
18:25
12/12/19
18:25
Hot Stocks
Adobe CEO: We are not overly concerned with the trade war with China »

Comment from interview…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 23

    Jan

SRPT

Sarepta

$100.39

-1.15 (-1.13%)

18:20
12/12/19
12/12
18:20
12/12/19
18:20
Hot Stocks
Sarepta announces FDA approval of VYONDYS 53 injection to treat DMD »

Sarepta Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,760.44

11.33 (0.65%)

18:11
12/12/19
12/12
18:11
12/12/19
18:11
Hot Stocks
Amazon orders fourth season of 'The Marvelous Mrs. Maisel' »

Amazon Studios announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OHAI

OHA Investment

$1.28

(0.00%)

, PTMN

Portman Ridge Finance

$2.04

(0.00%)

18:10
12/12/19
12/12
18:10
12/12/19
18:10
Hot Stocks
OHA Investment obtains stockholder approval of Portman Ridge deal »

OHA Investment…

OHAI

OHA Investment

$1.28

(0.00%)

PTMN

Portman Ridge Finance

$2.04

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ONCT

Oncternal Therapeutics

$4.62

0.05 (1.09%)

18:05
12/12/19
12/12
18:05
12/12/19
18:05
Hot Stocks
Oncternal presents interim data from Phase 1b clinical study of cirmtuzumab »

Oncternal Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HZN

Horizon Global

$3.49

0.14 (4.18%)

18:03
12/12/19
12/12
18:03
12/12/19
18:03
Hot Stocks
Horizon Global CFO Jamie Pierson steps down »

Horizon Global announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORCL

Oracle

$56.47

0.16 (0.28%)

18:03
12/12/19
12/12
18:03
12/12/19
18:03
Hot Stocks
Oracle CEO Catz says expects momentum in 2H20 to carry into FY21 »

Says feels "very…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

SRPT

Sarepta

$100.39

-1.15 (-1.13%)

18:00
12/12/19
12/12
18:00
12/12/19
18:00
Hot Stocks
Breaking Hot Stocks news story on Sarepta »

Sarepta trading halted,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORCL

Oracle

$56.47

0.16 (0.28%)

17:52
12/12/19
12/12
17:52
12/12/19
17:52
Hot Stocks
Oracle's Ellison says 'we have no plans for having a second CEO' »

Says there won't be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

NLNK

NewLink Genetics

$1.61

-0.015 (-0.93%)

, EVRC

Evercel, Inc

$0.00

(0.00%)

17:41
12/12/19
12/12
17:41
12/12/19
17:41
Hot Stocks
NewLink Genetics advances over 11% after Evercel discloses rejected offer »

Shares of NewLink…

NLNK

NewLink Genetics

$1.61

-0.015 (-0.93%)

EVRC

Evercel, Inc

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EVRC

Evercel, Inc

$0.00

(0.00%)

, NLNK

NewLink Genetics

$1.61

-0.015 (-0.93%)

17:36
12/12/19
12/12
17:36
12/12/19
17:36
Hot Stocks
Evercel announces rejected offer to acquire NewLink Genetics »

Evercel (EVRC) has made…

EVRC

Evercel, Inc

$0.00

(0.00%)

NLNK

NewLink Genetics

$1.61

-0.015 (-0.93%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BXRX

Baudax Bio

$6.30

0.225 (3.70%)

17:34
12/12/19
12/12
17:34
12/12/19
17:34
Hot Stocks
Corsair Capital reports 8.77% passive stake in Baudax Bio »

Corsair Capital disclosed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.